Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after HCV direct-acting antivirals

MLA

Faillaci, Francesca, et al. Liver Angiopoietin-2 Is a Key Predictor of de Novo or Recurrent Hepatocellular Cancer after HCV Direct-Acting Antivirals. Jan. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3674..2cc060e1d9d9d467bcffe0cc071a0aed&authtype=sso&custid=ns315887.

APA

Faillaci, F., Marzi, L., Critelli, R., Milosa, F., Schepis, F., Turola, E., Andreani, S., Vandelli, G., Bernabucci, V., Lei, B., D’Ambrosio, F., Bristot, L., Cavalletto, L., Chemello, L., Sighinolfi, P., Manni, P., Maiorana, A., Caporali, C., Bianchini, M., … Villa, E. (2018). Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after HCV direct-acting antivirals.

Chicago

Faillaci, Francesca, Luca Marzi, Rosina Critelli, Fabiola Milosa, Filippo Schepis, Elena Turola, Silvia Andreani, et al. 2018. “Liver Angiopoietin-2 Is a Key Predictor of de Novo or Recurrent Hepatocellular Cancer after HCV Direct-Acting Antivirals,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3674..2cc060e1d9d9d467bcffe0cc071a0aed&authtype=sso&custid=ns315887.